BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update

BioAge Labs, Inc. (NASDAQ:BIOA) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totaling 1,085,882 shares, a growth of 82.2% from the December 31st total of 596,127 shares. Based on an average daily trading volume, of 1,128,484 shares, the short-interest ratio is presently 1.0 days. Approximately 3.8% of the shares of the company are short sold. Approximately 3.8% of the shares of the company are short sold. Based on an average daily trading volume, of 1,128,484 shares, the short-interest ratio is presently 1.0 days.

BioAge Labs Stock Performance

Shares of NASDAQ:BIOA opened at $19.10 on Friday. The business has a fifty day moving average of $14.29 and a 200-day moving average of $8.58. BioAge Labs has a twelve month low of $2.88 and a twelve month high of $24.00. The firm has a market cap of $684.74 million, a PE ratio of -12.57 and a beta of 1.38.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The company had revenue of $2.05 million for the quarter.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BIOA. Citigroup upped their price objective on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday. Wall Street Zen lowered BioAge Labs from a “hold” rating to a “sell” rating in a research note on Monday. Finally, Piper Sandler assumed coverage on shares of BioAge Labs in a research note on Tuesday. They issued an “overweight” rating on the stock. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $15.00.

Insider Buying and Selling at BioAge Labs

In other BioAge Labs news, CFO Dov A. Md Goldstein sold 27,000 shares of the business’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total value of $531,900.00. Following the sale, the chief financial officer owned 22,408 shares of the company’s stock, valued at $441,437.60. The trade was a 54.65% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Paul D. Rubin sold 18,000 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $12.00, for a total transaction of $216,000.00. The SEC filing for this sale provides additional information. Insiders have sold 347,004 shares of company stock valued at $5,673,859 in the last 90 days. 20.82% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of BIOA. Police & Firemen s Retirement System of New Jersey bought a new position in BioAge Labs in the 2nd quarter valued at $27,000. Russell Investments Group Ltd. acquired a new position in shares of BioAge Labs during the third quarter valued at $27,000. CWM LLC boosted its holdings in BioAge Labs by 39.9% in the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after acquiring an additional 1,053 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after purchasing an additional 5,976 shares during the period. Finally, Public Employees Retirement System of Ohio bought a new stake in BioAge Labs during the 2nd quarter worth about $57,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.